Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 24 April 2012 | By Louise Zornoza,
The Public Consultation - CP No. 26 - on proposed new criteria for establishing the priority review for registration of medicines opened on April 20 and comments may be submitted within 30 days.
The proposal would grant priority review according to a points system to products that reach at least 10 points.
The application for prioritization would have to be made electronically and ANVISA would have 75 days to decide on petitions for priority registration, 90 days for post-registration priority, and 45 days for prior consent for clinical research.
ANVISA - Consulta Pública nº 26, de 11 de abril de 2012
Tags: Priority Review, CP No. 26, pharmaceutical, brazil, registration, drug